CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Naprelan

naproxen sodium· ingredient naproxenAntiinflammatory preparations, non-steroids for topical use· NAPROXEN SODIUM 375 mg/1; NAPROXEN SODIUM 500 mg/1; NAPROXEN SODIUM 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$9.28
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other naproxen products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Naproxen$0.05893−$9.22
Naprotin$0.06254−$9.21
24/7 Life by 7-Eleven Naproxen Sodium$0.06496−$9.21
Aleve$0.14651−$9.13
Naproxen Oral Suspension$0.17537−$9.10
Naproxen sodium$0.22001−$9.06
Aleve-D Sinus and Cold$0.24430−$9.03
Naproxen$1.91−$7.37

Medicare Part D coverage · CY2026

On 2 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.